Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Up-Front Osteosarcoma Resection: An Approach Worth Exploring?

December 16th 2020

R. Lor Randall, MD, FACS, discusses the concept and prospect of up-front resection in osteosarcoma from the Osteosarcoma Collaborative.

Janku Highlights PFS Benefit With Dose-Escalated Ripretinib in Advanced GIST

December 15th 2020

Filip Janku, MD, PhD highlighted a dose-escalated approach of ripretinib and how it yielded a progression-free survival benefit in patients with gastrointestinal stromal tumor across all lines of treatment in a phase 1 study.

Tumor Growth Rate Associated With Outcomes in Sarcoma Treated With Immunotherapy or Targeted Therapy

December 14th 2020

December 14, 2020 — A link between tumor growth rate and clinical outcomes was established in patients with sarcoma who received treatment with immunotherapy or targeted therapy.

Ripretinib Given as Intra-Patient Dose Escalation Shows Clinically Meaningful PFS in GIST After Disease Progression

November 30th 2020

November 30, 2020 - Dose escalation with ripretinib following disease progression on the 150-mg daily dose led to a clinically meaningful benefit in patients with advanced gastrointestinal stromal tumor.

FDA Approves Sonalleve MR-HIFU System for Osteoid Osteoma in the Extremities

November 30th 2020

November 30, 2020 - The FDA has approved the Sonalleve MR-guided high-intensity focused ultrasound (MR-HIFU) system for the treatment of patients with osteoid osteoma in the extremities.

Selinexor Improves PFS in Advanced Unresectable Dedifferentiated Liposarcoma

November 25th 2020

Selinexor demonstrated a statistically significant improvement in progression-free survival compared with matching placebo in patients with advanced unresectable dedifferentiated liposarcoma, following at least 2 prior treatments.

3D Printing Leads to Improved Precision and Reconstruction in Limb Salvage Surgery in Bone Tumors, Soft Tissue Sarcomas

November 24th 2020

R. Lor Randall, MD, FACS, discusses limb salvage surgeries that have been made possible through 3D printing, and the technological advances that are helping to increase precision and turnaround times.

Devimistat Granted Orphan Drug Status for Soft Tissue Sarcoma

November 24th 2020

November 24, 2020 — The FDA has granted an orphan drug designation to devimistat for the treatment of patients with soft tissue sarcoma.

Pexidartinib Demonstrates Long-Term Efficacy, Safety in Tenosynovial Giant Cell Tumors

November 24th 2020

November 24, 2020 - Pexidartinib was found to result in prolonged efficacy with favorable safety in patients with tenosynovial giant cell tumors, according to long-term data from a pooled analysis of 3 cohorts of patients who received the agent.

Ripretinib Shows Antitumor Activity in Fourth-Line KIT/PDGFRA-Mutated Advanced GIST

November 23rd 2020

November 23, 2020 - Ripretinib demonstrated clinically meaningful activity in patients with fourth-line or later advanced gastrointestinal stromal tumor and several, heterogeneous genetic subsets of KIT/PDGFRA mutations.

Dr. Trent on the Potential Role of Immunotherapy in GIST

November 19th 2020

Jonathan C. Trent, MD, PhD, discusses the potential role of immunotherapy in gastrointestinal stromal tumors.

Moffitt Expert Emphasizes Need to Improve Sarcoma Diagnoses

November 19th 2020

Marilyn M. Bui, MD, PhD, highlights the importance of pathology in sarcoma and how it is the cornerstone of precision medicine.

FDA Grants PTC596 Multiple Designations for Leiomyosarcoma, Glioma

November 18th 2020

November 18, 2020 - The FDA has granted a fast track designation and an orphan drug designation to the orally bioavailable small molecule tubulin-binding agent PTC596 for potential use in patients with leiomyosarcoma; the agent also received a rare pediatric disease designation and an orphan drug designation for potential use in patients with diffuse intrinsic pontine glioma.

Dr. Randall on the Evolution of Orthopedic Surgery in Sarcoma

November 16th 2020

R. Lor Randall, MD, FACS, discusses the evolution of orthopedic surgery in sarcoma.

Nivolumab/Ipilimumab Combo Is Effective, Safe in Advanced or Unresectable Angiosarcoma

November 13th 2020

November 13, 2020 - The combination of nivolumab and ipilimumab elicited an objective response rate of 25% and was found to be well tolerated in patients with advanced or unresectable angiosarcoma, according to cohort findings of the phase 2 DART trial.

Dr. Zalcberg on the Approval of Avapritinib in GIST

November 12th 2020

John Zalcberg, PhD, OAM, discusses the approval of avapritinib in gastrointestinal stromal tumor.

Dr. Abraham on Surgical Improvements in TGCT

November 5th 2020

John A. Abraham, MD, FACS, discusses surgical improvements in tenosynovial giant cell tumor.

JTCC and Georgetown’s Alliance in Cancer Research Achieves New Level With Immunotherapy Breakthrough

November 4th 2020

It was 5:00 PM on a Monday, and Andrew Pecora, MD, FACP, CPE, was just wrapping up his practice for the day when one of his nurses came to the door, asking if he could see one more patient.

Dr. Tap on Future Research Efforts in Sarcoma

November 4th 2020

William D. Tap, MD, discusses future research efforts in sarcoma.

Selinexor Significantly Improves PFS in Unresectable Dedifferentiated Liposarcoma

November 3rd 2020

Single-agent selinexor resulted in a statistically significant prolongation of progression-free survival in patients with advanced unresectable dedifferentiated liposarcoma, meeting the primary end point of the phase 3 SEAL trial.